Clinical Trial Update: A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) [Phase 2]

View source ↗

Summary

A three-arm Phase II clinical trial evaluates dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynecologic clear cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Clear Cell Carcinoma
• Endometrial Cancer
• Ovarian Cancer
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Avastin (bevacizumab)
• JEMPERLI (DOSTARLIMAB)

Snippet

Sponsor: Yonsei University | Conditions: Ovarian Neoplasms, Endometrial Neoplasms | Phase 2 | Status: RECRUITING